Nurix Therapeutics, Inc.: Form 10-K for the period ended Nov 30, 2021
Filed with the SEC on Jan 28, 2022 and accepted by EDGAR at Jan 28, 2022, 16:11 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2021-11-30. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 12 months2020-12-01 to 2021-11-30 | $29.8m | us-gaap:Revenues |
| Research and development | 12 months2020-12-01 to 2021-11-30 | $116.4m | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 12 months2020-12-01 to 2021-11-30 | −$117.9m | us-gaap:OperatingIncomeLoss |
| Income tax | 12 months2020-12-01 to 2021-11-30 | $131.0k | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 12 months2020-12-01 to 2021-11-30 | −$117.2m | us-gaap:NetIncomeLoss |
| Operating cash flow | 12 months2020-12-01 to 2021-11-30 | −$84.4m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 12 months2020-12-01 to 2021-11-30 | $5.7m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | At period end2021-11-30 | $80.5m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2021-11-30 | $311.1m | us-gaap:AssetsCurrent |
| Total assets | At period end2021-11-30 | $476.8m | us-gaap:Assets |
| Current liabilities | At period end2021-11-30 | $66.3m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2021-11-30 | $134.5m | us-gaap:Liabilities |
| Shareholders' equity | At period end2021-11-30 | $342.3m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001564590-22-003007. Last ingested by Listed: Nov 5, 2026, 13:59 ET. Listed shows no prices and gives no investment advice.